AZILSARTAN

 
AzilsartanMedoxomil Potassium
 

(5-methyl-2-oxo-l,3-dioxol-4-yl)methyl 2- ethoxy- 1 - { [2'-(5-oxo-4,5-dihydro- 1 ,2,4-oxadiazol-3-yl)biphenyl-4yl]methyl} - 1 H- benzimidazole-7-carboxylate monopotassium salt

NMR  http://file.selleckchem.com/downloads/nmr/S305702-Azilsartan-Medoxomil-NMR-Selleck.pdf

AzilsartanMedoxomil Potassium is chemically named as (5-Methyl-2-oxo-1, 3-dioxol-4yl) methyl 2-ethoxy-1-{[2- (5-oxo-4, 5-dihydro-1, 2, 4-oxadiazol-3-yl) biphenyl-4-yl]methyl}- 1H-benzimidazole-7-carboxylatemonopotassium salt. Azilsartanmedoxomil is the prodrug of 2-ethoxy-1-([2'-(5-oxo4,5 – dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4- yl]methyl) 1H-benimidazole-7-carboxylic acid.It is a white crystalline powder insoluble in water, slightly soluble in solvents such as acetone, and acetonitrile, freely soluble in methanol, dimethylsulfoxide, and dimethylformamide, soluble in solvents such as acetic acid, and very slightly soluble in solvents tetrahydrofuran and 1-octanol.

The US Food and Drug Administration (FDA) has approved Edarbi tablet (AzilsartanMedoxomil Potassium) on February 25, 2011, to treat hypertension in adults. It is available in 80mg and 40 mg dosages, with the recommended dosage set at 80mg once in a day [1].

Angiotensin II hormone plays a vital role in activation of renin-angiotensinaldosterone systems well as in regulation of blood pressure, fluid-electrolyte balance, and also in pathophysiology of hypertension. Activation of type 1 angiotensin receptor which is a member of G protein coupled receptor efficiently controls the numerous effects of AII which are vasoconstriction, secretion of aldosterone and vasopressin and cellular proliferation. So blocking of AII receptor will also block receptor-1, and it will lead to termination of the whole course of action mentioned above;

so all blocker will be helpful in the management of cardiovascular and renal diseases as therapeutic agent.The active moiety of AMP is revealed by hydrolysis of the medoxomil ester and it converts into azilsartan which is an active angiotensin II receptor blocker and more effective in lowering blood pressure within 24 hours as compared to valsartan and olmesartan[2-5].There are several methods that are reported for preparation of azilsartan [6-15].

The presence of related substances in an active pharmaceutical ingredient (API) can have a significant impact on the quality and safety of the drug products. Therefore, it is necessary to study the impurity (related substance) profile of the API to be used in the manufacturing of the drug product. International Conference on Harmonization (ICH)guidelines recommends identifying and characterizing all related substancesthat are present at level less than 0.10% [16].

AZILSARTAN

2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
CAS No.:	147403-03-0
Synonyms:	UNII-F9NUX55P23; 1H-Benzimidazole-7-carboxylic acid,1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy; TAK 536; azilsartan acid; Azilsartan;
Formula:	C25H20N4O5
Exact Mass:	456.14300

 

1H NMR PREDICT

 

13 C NMR PREDICT

 

AZILSARTAN MEDOXIMIL

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
CAS No.:	863031-21-4
Synonyms:	View More Azilsartan Medoxomil; Azilsartan (medoxomil); Azilsartan; azilsartan medoxomilo; azilsartanum medoxomilum; UNII-LL0G25K7I2; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate; [14C]-Azilsartan medoxomil; Edarbi; TAK 491; Azilsartan kamedoxomil; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester of 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid;
Formula:	C30H24N4O8
Exact Mass:	568.15900

Cited Patent	Filing date	Publication date	Applicant	Title
WO2012107814A1 *	Jan 24, 2012	Aug 16, 2012	Jubilant Life Sciences Limited	An improved process for the preparation of azilsartan medoxomil
US5243054 *	Jun 25, 1992	Sep 7, 1993	Takeda Chemical Industries, Ltd.	Compound which is angiotensin ii antagonist
US20050187269 *	Jan 7, 2005	Aug 25, 2005	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof

Citing Patent	Filing date	Publication date	Applicant	Title
WO2013186792A2 *	Jun 6, 2013	Dec 19, 2013	Msn Laboratories Limited	Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts

REFERENCES
[1] M. Gasparo, K. J. Catt, T. Inagami, J.W. Wright, T. Unger, Pharmacol. Rev.2000, 52, 415

[2] W.B. White, M.A. Weber, D. Sica, G.L. Bakris,A. Perez,C. Cao, S. Kupfer, Hypertension.2011, 57, 413.

[3] G.L.Bakris, D.Sica, M.Weber, W.B. White,A. Roberts,A. Perez, C. Cao, S. J. Kupfer, Clin. Hypertens.2011, 13, 81.

[4] D. Sica, W.B. White, M.A. Weber, G.L. Bakris, A. Perez,C. Cao,A. Handley, S. Kupfer, J. Clin. Hypertens. 2011, 13, 467.

[5] H. Rakugi, K. Enya, K. Sugiura, Y. Ikeda, Hypertens. Res.2012, 35, 552.

[6] Y. Kohara, E. Imamiya, K. Kubo, T. Wada, Y. Inada, T. Naka, Bioorg. Med. Chem. Lett.1995, 5, 1903.

[7] T. Naka,Y. Inada, U.S. Patent 5583141 (1996) [8] T. Naka, Y. Inada, Eur Pat. Appl. EP 0520423, (1992)

[9] Y. Kohara, K. Kubo,E. Imamiya, T. Wada, Y. Inada, T. Naka, J. Med. Chem.1996, 39, 5228.

[10] T. Kuroita, H. Sakamoto,M.Ojima, U.S. Pat. Appl. 0187269 (2005) [11] T. Kuroita, H. Sakamoto, M. Ojima, U.S. Pat. Appl. 7157584 (2007) [12] S. Radl, J. Cerny,J. Stach, Z. Gablíkova, Org. Process Res. Dev.2013, 17, 77

[13] A. Agarwal, D. Bansal, A.S. Choudhary, S.K. Dubey, H. Mishra, D. Vir, WO 2012107814 A8 (2012)

[14] S.D. Dwivedi, K.K. Singh, J.T. Gajera, US 20140113942 A1, (2014)

[15] D. Bansal,H. Mishra,S.K. Dubey, A.S. Choudhary, D. Vir, A. Agarwal, A. Daz, US 20130317230 A1 (2013)

[16] International Conference of Harmonization (ICH). Q3A(R) Related substance/Impurities in New Drug Substance, Feb. 2002.

 KARACHI, PAKISTAN











 
 Skyline of Karachi as seen from the I.I. Chundrigar Road.





 

 

 Karachi Municipal Corporation Building situated at M.A Jinnah Road and a sight of Downtown Karachi.



 

 


 Karachi is called the “City of Lights” by Pakistani people. Enjoy the majesty of Karachi; the birth place of Quaid-e-Azam Muhammad Ali Jiannah


 

 

 

Points of interest

View 15+ more

Clifton Beach, Karachi

Mohatta Palace

Mazar‑e‑Quaid

Frere Hall

PAF Museum, Karachi

Colleges and Universities

View 45+ more

University of Karachi

NED University of Engine...

Iqra University

Shaheed Zulfiqar Ali Bhutto Ins...

Aga Khan University

Ethyl 4-nitrobenzoate NMR

Ethyl 4-nitrobenzoate

• CAS Number 99-77-4
   

13 C NMR

1H NMR












IR









Ms











INTRODUCTION OF AMINO GROUP

 ethyl-p-aminobenzoate.



Shift (ppm)
167.4 114.1
151.5 60.6
132.0 14.7
120.0





picked up from a japanese site

₉H₁₁NO₂)の¹H-NMRスペクト ル (300MHz)である。図アを示す化合物はIRスペクトル (neat)にて1700 cm^-1付近に、又、図イを示す化合物はIRスペクトル (Nujol)にて 1650 cm^-1付近に共に強い吸収を示す。スペクトルと化合物の正し い組合せはどれか。ただし、図アの3.4 ppm付近、図イの6.3 ppm付近及び7.9 ppm付近のシグナルは重水処理すると消失する。また測定溶媒に基づくシグナ ルは除いてある。

　a　2-ethoxybenzamide
　b　4-ethoxybenzamide
　c　ethyl 3-aminobenzoate
　d　ethyl 4-aminobenzoate

　　　 ア　イ　
　　1　a　c　
　　2　a　d　
　　3　b　c
　　4　b　d　
　　5　c　a　
　　6　c　b

is (a and a) the figure below (C any compound that is shown in a ~ D ₉ H ₁₁ NO ₂ of) ¹ H-NMR spectrum is (300MHz). 1700 cm IR spectrum at (neat) compounds exhibit a Zua ^-1 in the vicinity, also, compounds that exhibit a spinal is 1650 cm IR spectrum at (Nujol) ^-1 shows a strong absorption both in the vicinity. Right combination of compounds and any spectrum. However, I lost signal around 3.4 ppm of Zua, of around 7.9 ppm and 6.3 ppm near the spinal when you heavy water processing. The signal based on the measurement solvent have been removed. 　a 2-Ethoxybenzamide 　b 4-Ethoxybenzamide 　c ethyl 3-Aminobenzoate 　D ethyl 4-Aminobenzoate

　　　 Eye　
　　1 a c　
　　2 a D　
　　b 3 c
　　4 b D　
　　c 5 a　
　　6 c b

THANE INDIA


































..............